Perspective of the risk and molecular mechanisms of hepatocellular carcinoma after HCV eradication in the post-DAA era: Correspondence to editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”

Bibliographic Details
Published in:	Clinical and Molecular Hepatology
Main Authors:	Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu
Format:	Article
Language:	English
Published:	Korean Association for the Study of the Liver 2024-10-01
Subjects:	hcv daa svr
Online Access:	http://e-cmh.org/upload/pdf/cmh-2024-0472.pdf

Similar Items

Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
by: Chung-Feng Huang, et al.
Published: (2024-07-01)

Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-directacting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”
by: Seren M. Gedallovich, et al.
Published: (2024-10-01)

DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C
by: Xiaobo Zhu, et al.
Published: (2024-10-01)

Clinical and Molecular Basis of Hepatocellular Carcinoma after Hepatitis C Virus Eradication
by: Natsumi Oe, et al.
Published: (2022-04-01)

Cure or curd: Modification of lipid profiles and cardio‐cerebrovascular events after hepatitis C virus eradication
by: Chung‐Feng Huang, et al.
Published: (2020-11-01)

Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan
by: Chen-Ta Chi, et al.
Published: (2021-06-01)

Predictors of hepatocellular carcinoma recurrence associated with the use of direct‐acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study
by: Masahito Nakano, et al.
Published: (2019-05-01)

Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness
by: Elton Dajti, et al.
Published: (2021-06-01)

Seven gene signature explores the impact of DAAs on the appearance of hepatocellular carcinoma in HCV infected patients
by: Reham M. Dawood, et al.
Published: (2022-08-01)

HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance
by: Devis Pascut, et al.
Published: (2020-06-01)

Long-Term Outcomes of Patients with Liver Cirrhosis After Eradication of Chronic Hepatitis C with Direct-Acting Antiviral Drugs (DAAs)
by: Salama M, et al.
Published: (2024-10-01)

Worsening of Controlled Attenuation Parameter and Metabolic Profile After HCV Cure in People with HIV as a Sign of Steatosis
by: Alessia Siribelli, et al.
Published: (2025-06-01)

Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study)
by: Chung-Feng Huang, et al.
Published: (2025-04-01)

Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry
by: Tyng-Yuan Jang, et al.
Published: (2025-08-01)

Baseline serum EV-miR-1-3p as a protective factor and biomarker for hepatocellular carcinoma development after HCV eradication
by: Wei Teng, et al.
Published: (2025-07-01)

The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma
by: Yu-Syuan Chen, et al.
Published: (2022-02-01)

Real-Life Data of Chronic Hepatitis C Patients Treated with Direct-Acting Oral Antivirals: A Single-Center Study
by: Umut Devrim Binay, et al.
Published: (2023-05-01)

Micro-elimination of hepatitis C virus infection in the rural and remote areas of Taiwan – A multi-center collaborative care model
by: Ching-Chu Lo, et al.
Published: (2023-08-01)

Real world experience with the all-oral interferon free regimen for the treatment of chronic hepatitis c virus infection in the Lebanese population
by: Jowana Saba, et al.
Published: (2018-02-01)

HEPATITIS C VIRUS – FROM UNKNOWN VIRUS TO A CURABLE DISEASE
by: Raluca Mihaela Dirtu, et al.
Published: (2019-06-01)

Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections
by: Mohammad Asrar Izhari
Published: (2023-09-01)

Persistence of Hepatocellular Carcinoma Risk after Hepatitis C Virus Eradication
by: Sojung Han, et al.
Published: (2020-05-01)

Hepatocellular Carcinoma Risk, Outcomes, and Screening After Hepatitis C Eradication
by: Roberta D’Ambrosio, et al.
Published: (2021-09-01)

Predictive Factors for Hepatocellular Carcinoma Development after Direct-Acting Antiviral Treatment of HCV
by: Zuzana Macek Jilkova, et al.
Published: (2021-12-01)

Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan”
by: Chung-Feng Huang, et al.
Published: (2025-01-01)

HCV eradication in people living with HIV: the final countdown?
by: A. De Vito, et al.
Published: (2021-02-01)

Impact of interferon-free regimens in patients with chronic HCV and successfully ablated HCC
by: Amr Maged Mahmoud Rasheed, et al.
Published: (2025-02-01)

Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
by: Jingjing Wu, et al.
Published: (2019-01-01)

Hepatocellular carcinoma after eradication of hepatitis C virus
by: Hamid HADJAISSA, et al.
Published: (2023-04-01)

Prediction Model for Risk of Hepatocellular Carcinoma After Hepatitis C Viral Eradication
by: Hsu WF, et al.
Published: (2025-10-01)

Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
by: Seren M. Gedallovich, et al.
Published: (2024-10-01)

Smallpox in the Post-Eradication Era
by: Hermann Meyer, et al.
Published: (2020-01-01)

Efficacy and safety of directly acting antiviral drugs in HCV patients with HIV in liver transplantation: A meta-analysis
by: Tian Zeng, et al.
Published: (2023-01-01)

Critical role of triglycerides for adiponectin levels in hepatitis C: a joint study of human and HCV core transgenic mice
by: Ming-Ling Chang, et al.
Published: (2021-08-01)

Peripheral Neuropathy in Patients with Hepatitis C Infection—Reversibility after HCV Eradication: A Single Center Study
by: Theodoros Androutsakos, et al.
Published: (2024-03-01)

Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus
by: Nobuharu Tamaki, et al.
Published: (2022-03-01)

Dynamic Prediction of the Risk of Hepatocellular Carcinoma After DAA Treatment for Hepatitis C Patients
by: Xinyan Ma MS, et al.
Published: (2025-01-01)

Retrieval of HCV patients lost to follow-up as a strategy for Hepatitis C Microelimination: results of a Brazilian multicentre study
by: Maria Lucia Gomes Ferraz, et al.
Published: (2023-07-01)

Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals
by: Nițescu Maria, et al.
Published: (2017-10-01)

Elimination of HCV replication machinery early after antiviral treatment with DAA monitored by multimodal microscopy
by: Castro Victoria, et al.
Published: (2024-01-01)